BioStock interviews Enzymatica’s CEO on the company’s next phase of development

In a recent interview with BioStock, Enzymatica’s CEO Sana Alajmovic reflects on her first weeks in the role and outlines the company’s ambitions going forward. 

The conversation highlights Enzymatica’s strong scientific foundation and the clear differentiation of ColdZyme through its clinical evidence. Sana also discusses the ongoing efforts to deepen dialogues with potential partners in Europe and the ambition to drive a structured and capital-efficient international expansion.

At the same time, Sweden continues to perform strongly, providing both momentum and valuable insights for the next phase of growth.

Read the full interview at BioStock - Enzymatica gears up under new leadership – focus on international expansion